Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675934 | 0.92 | GSK3B (0.39) | GSK3BCYP1A2AAK1GSK3AACHE | |
| SCHEMBL16682170 | 0.89 | GSK3B (0.43) | GSK3BCYP1A2AAK1GSK3AACHE | |
| SCHEMBL16675962 | 0.82 | GSK3B (0.40) | GSK3BCYP1A2AAK1GSK3AMAPK1 | |
| SCHEMBL16682116 | 0.81 | GSK3B (0.44) | GSK3BCYP1A2GSK3AACHE | |
| SCHEMBL16675897 | 0.81 | PLK4 (0.40) | — | |
| SCHEMBL16675955 | 0.78 | GSK3B (0.43) | GSK3BCYP1A2KDR | |
| SCHEMBL18556908 | 0.77 | CYP2D6 (0.44) | CYP1A2 | |
| SCHEMBL16675957 | 0.77 | GSK3B (0.44) | GSK3BCYP1A2AAK1GSK3AACHE | |
| SCHEMBL16675942 | 0.74 | GSK3B (0.48) | GSK3BCYP1A2AAK1GSK3A | |
| SCHEMBL16675950 | 0.74 | GSK3B (0.43) | GSK3BAAK1MAPK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | GSK3B 4407/4885CYP1A2 2648/4885AAK1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.